ABSTRACT:
Diacerein, an anti-inflammatory modulator of connective tissue, has significant adverse effects and is poorly soluble. To improve Diacerein bioavailability, stability, and controlled release and reduce adverse effects, the study investigates nanosponges (NSs) as a novel drug delivery method. Because NSs are porous particles, they provide targeted delivery and substantial drug loading. The emulsion solvent diffusion process was used to formulate Diacerein nanosponges, which are then compressed into tablets. The formulated nanosponges outperformed a commercial DC product with good flow properties, consistent weight, reduced friability, and regulated drug release over 7 hours. It is clear from the disintegration time of 10.48±0.38 minutes that the tablets dissolve well, allowing for quick therapeutic action. The prompt release of the active ingredient, which increases the medication's therapeutic efficacy, depends on this quick disintegration. Under accelerated settings (40±20°C at 75% RH), stability experiments conducted over 30 and 60 days showed negligible fluctuations in drug content (83.21±0.68% to 83.16±0.49%) and hardness (3.51±0.3 to 3.45±0.02 Kg/cm²), as well as stable in vitro drug release (74.22% to 74.06%). First-order kinetics were followed by the in vitro drug release, suggesting a concentration-dependent mechanism. According to this study, Diacerein loaded nanosponge tablets provide a potentially effective way to treat osteoarthritis by delivering targeted, controlled medication release that is more stable and has fewer adverse effects.